Oculis Announces US Public Listing on Nasdaq

Starting today, Oculis’ shares will trade on the Nasdaq Stock Market under the ticker symbol "OCS."

The listing comes after successfully closing the business combination between European Biotech Acquisition Corp. (EBAC) and Oculis SA. The business combination was unanimously approved by the board of directors and shareholders of Oculis SA and by the EBAC shareholders at an extraordinary general meeting on February 28, 2023. 

"Listing on the Nasdaq Stock Market is a major corporate milestone for Oculis and its investors," Riad Sherif MD, CEO of Oculis, said in a company news release. "It is a confirmation of the potential of Oculis’ pipeline to bring significant value for patients, physicians and investors. Oculis' robust financial position enables the advancement of multiple clinical stage candidates and the delivery of several important near-term catalysts for value creation, including potentially OCS-01, the first topical eye-drop for DME, OCS-02, the first biologic eye-drop for dry eye disease (DED) and OCS-05, the first neuroprotective agent for neuro-retina diseases, such as Acute Optic Neuritis (AON) and glaucoma." 

Upon closing, Oculis had a pro-forma enterprise value of approximately $220 million and a cash balance exceeding $117 million, prior to payment of final transaction costs. Oculis is supported by new and existing institutional investors in the upsized PIPE financing including LSP 7, funds managed by Tekla Capital Management LLC, Earlybird, Novartis Venture Fund, Pivotal Life Sciences and VI Partners, among others. 

Oculis’ Board of Directors now comprises seven members, including six directors who are "independent" as per Nasdaq listing standards. Anthony Rosenberg will continue to serve as Chairman of the Board of Directors, which now includes Christina Ackermann; Lionel Carnot; Pravin Dugel MD; Martijn Kleijwegt; Geraldine O’Keeffe; and Riad Sherif, MD.